---
title: "JINLING PHARM.: Fuzhou Meifeng Pharmaceutical Factory's hydrolyzed protein injection has received re-registration approval"
description: "JINLING PHARM.'s Fuzhou Meifeng Pharmaceutical Factory has received approval from the Fujian Provincial Drug Administration for the re-registration of hydrolyzed protein injection. The specification o"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/253765025.md"
published_at: "2025-08-20T08:25:50.000Z"
---

# JINLING PHARM.: Fuzhou Meifeng Pharmaceutical Factory's hydrolyzed protein injection has received re-registration approval

> JINLING PHARM.'s Fuzhou Meifeng Pharmaceutical Factory has received approval from the Fujian Provincial Drug Administration for the re-registration of hydrolyzed protein injection. The specification of this drug is 500ml:25g, mainly used for severe amino acid deficiency and hypoproteinemia. Although the approval helps restore production and sales, the recent performance impact is minimal, and market and policy factors bring uncertainty, reminding investors to pay attention to risks

On August 20, 2025, JINLING PHARM. announced that its subsidiary Fuzhou Meifeng Pharmaceutical Factory recently received the re-registration approval notice for hydrolyzed protein injection from the Fujian Provincial Drug Administration. The drug acceptance number is CYHZ2514512 Min, with a specification of 500ml:25g, classified as a chemical drug. Due to long-term suspension of production, resuming production requires an on-site inspection application to the provincial drug administration, and the drug can only be marketed after passing the inspection and sampling. Hydrolyzed protein injection is used for severe amino acid deficiency and hypoproteinemia. The re-registration is beneficial for the drug's production and sales recovery, but it has no significant impact on recent performance, and the production and sales of the drug are subject to uncertainties influenced by policies, market conditions, and other factors, reminding investors to pay attention to risks

### Related Stocks

- [000919.CN - JINLING PHARM.](https://longbridge.com/en/quote/000919.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| New study finds early hormone replacement therapy reduces risk of osteoporosis and fractures for older women | A new study presented at the 2026 AAOS Annual Meeting reveals that early hormone replacement therapy (HRT) significantly | [Link](https://longbridge.com/en/news/277412093.md) |
| SSY Group's Respiratory Drug Approved for Production in China | SSY Group's Respiratory Drug Approved for Production in China | [Link](https://longbridge.com/en/news/277561555.md) |
| How can I systematically track high-win-rate wallet addresses on Polymarket? | The article discusses strategies for tracking high-win-rate wallet addresses on Polymarket, emphasizing the importance o | [Link](https://longbridge.com/en/news/277561416.md) |
| LESS NOISE, BETTER SIGNALS: HOW PHARMA CAN MEASURE IMPACT AS AI RESHAPES SEARCH | The article discusses the transformation of search in the pharmaceutical industry due to AI adoption, emphasizing the sh | [Link](https://longbridge.com/en/news/277470520.md) |
| Does RFK Jr. care that babies will needlessly die under his vaccination policies? | The article discusses the impact of Robert F. Kennedy Jr.'s vaccination policies, highlighting a resurgence of measles c | [Link](https://longbridge.com/en/news/277225914.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.